First test of new hives drug begins in humans
Disease control
Recruiting now
This is the first study in people to test the safety of a new drug called GTX-B001. It will be given as a single dose to 48 healthy volunteers and 24 people with chronic hives triggered by cold or scratching. The main goal is to see how safe the drug is and how the body processes…
Phase: PHASE1 • Sponsor: Granular Therapeutics Limited • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC